Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Surgery. 2014 Jun 2;156(3):548–555. doi: 10.1016/j.surg.2014.04.014

Figure 2. Uptake of exosomal CCN2-GFP by mouse HSC or human LX-2 cells.

Figure 2

(A) Uptake of PKH26-labeled HSC-derived exosomes by activated HSC after 24 hours. PKH26 is in red and DAPI nuclear stain is in blue. Data are representative of five independent experiments. (B) Quantitative RT-PCR of GFP mRNA in donor HSC transfected with a CCN2-GFP fusion vector (left), exosomes isolated from CCN2-GFP-transected HSC (center) or recipient HSC after incubation with the exosomes for 24 hours (right). (C) Western blotting with anti-GFP to detect CCN2-GFP in lysates of CCN2-GFP-transfected donor HSC (left), CCN2-GFP in their secreted exosomes (center), or CCN2-GFP or CD9-GFP in lysates of recipient cells incubated with CCN2-GFP- or CD9-GFP-containing exosomes for 2 or 6 hours in the presence of absence of cylcoheximide (right). (D) Uptake by LX-2 cells of PKH26-labeled LX-2 cell-derived exosomes. Data are representative of 4 independent experiments. (E) qRT-PCR for GFP mRNA in LX-2 cells incubated for 2-24 hours with exosomes isolated from CCN2-GFP-transected LX-2 cells. (F) Western blotting with anti-GFP to detect CCN2-GFP in lysates of recipient LX-2 cells incubated for 2-24 hours with CCN2-GFP-containing LX-2 cell-derived exosomes.

HHS Vulnerability Disclosure